Fenbendazole, originally created as an animal anthelmintic, is currently being used by humans on an experimental basis. The drug has a good track record for safety in animals, and is generally well tolerated by humans, which has led to the creation of the “Joe Tippens Protocol” (see Health Feedback’s previous article on this).
It is believed that the protocol works by combining fenbendazole with DCA, a compound also used as an antiparasitic agent. Both of these drugs are part of the benzimidazole family, which has been shown to exhibit cancer fighting properties in laboratory experiments.
Some studies have shown that fenbendazole can slow down cancer cell growth in test tubes and in animal models. It is also thought that the drug could be used to treat other cancers, such as lung cancer that has a KRAS mutation, by targeting the tumor’s microtubules.
However, in order to arrive at more reliable conclusions, randomized clinical trials involving many patients would need to be performed first. And while there are several anecdotal stories of people who have been in remission after using fenbendazole, it’s important to note that these stories may simply be due to other factors, such as conventional cancer treatments that weren’t taken into account.
A recent study has found that fenbendazole causes the death of colorectal cancer cells by disrupting their microtubules and interfering with their protein production. The study also found that fenbendazole caused the accumulation of free iron through the inhibition of cysteine uptake by SLC7A11 and inactivation of GPX4. This excess iron promotes ferroptosis, which is a form of cellular suicide characterized by lipid peroxidation.
The researchers found that fenbendazole not only destabilized microtubules in the cells, but also inhibited cellular proliferation and induced apoptosis through the p53-p21 pathway in CRC cells. Moreover, the benzimidazole caramate induced preferential elimination of cancer cells and suppressed tumor growth by disrupting the microtubules, stabilizing p53 and inhibiting glucose metabolism in the cells. This is the first time that this has been reported for a cancer-fighting drug in the benzimidazole family. The findings support the hypothesis that the combination of fenbendazole and DCA is an effective treatment for cancer. The results also suggest that this combination has the potential to improve treatment outcomes in combination with other therapies, such as immunotherapy. The researchers are planning to conduct further experiments to determine the optimal combination of fenbendazole with other agents that can enhance its antitumor effects. fenbendazole for humans